Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
31
LIXT Quote, Financials, Valuation and Earnings
Last price:
$3.00
Seasonality move
:
7.58%
Day range:
$2.84 - $3.08
52-week range:
$0.64 - $6.26
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
7.13x
Volume:
78.8K
Avg. volume:
90.9K
1-year change:
5.34%
Market cap:
$16.8M
Revenue:
--
EPS (TTM):
-$1.18
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LIXT
Lixte Biotechnology Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.21 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 110.49% | -58.59% | $479.79 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$835.5M | $0.70 | 11.91% | 37.43% | $89.09 |
|
IMNN
Imunon, Inc.
|
-- | -$1.82 | -- | -269.06% | $21.50 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LIXT
Lixte Biotechnology Holdings, Inc.
|
$2.95 | -- | $16.8M | -- | $0.00 | 0% | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$23.56 | $31.21 | $4B | 15.16x | $0.00 | 0% | 3.79x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$328.16 | $479.79 | $43.4B | 1,364.49x | $0.00 | 0% | 13.46x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$58.13 | $89.09 | $11.2B | 21.78x | $0.00 | 0% | 3.68x |
|
IMNN
Imunon, Inc.
|
$3.27 | $21.50 | $6.9M | -- | $0.00 | 0% | 16.43x |
|
SVRA
Savara, Inc.
|
$5.30 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LIXT
Lixte Biotechnology Holdings, Inc.
|
-- | 3.599 | 0.16% | 10.25x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
92.22% | 1.064 | 4.61% | 2.37x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.17% | -0.896 | 5.87% | 2.84x |
|
IMNN
Imunon, Inc.
|
21.26% | 5.236 | 10.13% | 1.25x |
|
SVRA
Savara, Inc.
|
24.02% | -1.971 | 4.83% | 7.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LIXT
Lixte Biotechnology Holdings, Inc.
|
-- | -$1.8M | -228.97% | -228.97% | -- | -$926.8K |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1B | $368M | 1.51% | 31.15% | 29.46% | $313M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$641.8M | $184.9M | 8.12% | 8.99% | 23.5% | $334.9M |
|
IMNN
Imunon, Inc.
|
-$167K | -$3.5M | -282.76% | -365% | -- | -$4.4M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
Lixte Biotechnology Holdings, Inc. vs. Competitors
-
Which has Higher Returns LIXT or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Lixte Biotechnology Holdings, Inc.'s net margin of 25.76%. Lixte Biotechnology Holdings, Inc.'s return on equity of -228.97% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital LIXTLixte Biotechnology Holdings, Inc.-- -$0.33 $4.9M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About LIXT or ACAD?
Lixte Biotechnology Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 32.03%. Given that ACADIA Pharmaceuticals, Inc. has higher upside potential than Lixte Biotechnology Holdings, Inc., analysts believe ACADIA Pharmaceuticals, Inc. is more attractive than Lixte Biotechnology Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LIXTLixte Biotechnology Holdings, Inc.0 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is LIXT or ACAD More Risky?
Lixte Biotechnology Holdings, Inc. has a beta of 0.929, which suggesting that the stock is 7.054% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock LIXT or ACAD?
Lixte Biotechnology Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lixte Biotechnology Holdings, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LIXT or ACAD?
Lixte Biotechnology Holdings, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Lixte Biotechnology Holdings, Inc.'s net income of -$2M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Lixte Biotechnology Holdings, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 15.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lixte Biotechnology Holdings, Inc. is -- versus 3.79x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LIXTLixte Biotechnology Holdings, Inc.-- -- -- -$2M ACADACADIA Pharmaceuticals, Inc.3.79x 15.16x $278.6M $71.8M
-
Which has Higher Returns LIXT or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Lixte Biotechnology Holdings, Inc.'s net margin of 20.1%. Lixte Biotechnology Holdings, Inc.'s return on equity of -228.97% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.
Company Gross Margin Earnings Per Share Invested Capital LIXTLixte Biotechnology Holdings, Inc.-- -$0.33 $4.9M ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B -
What do Analysts Say About LIXT or ALNY?
Lixte Biotechnology Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $479.79 which suggests that it could grow by 46.21%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Lixte Biotechnology Holdings, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Lixte Biotechnology Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LIXTLixte Biotechnology Holdings, Inc.0 0 0 ALNYAlnylam Pharmaceuticals, Inc.13 8 0 -
Is LIXT or ALNY More Risky?
Lixte Biotechnology Holdings, Inc. has a beta of 0.929, which suggesting that the stock is 7.054% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock LIXT or ALNY?
Lixte Biotechnology Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lixte Biotechnology Holdings, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LIXT or ALNY?
Lixte Biotechnology Holdings, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. Lixte Biotechnology Holdings, Inc.'s net income of -$2M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, Lixte Biotechnology Holdings, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,364.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lixte Biotechnology Holdings, Inc. is -- versus 13.46x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LIXTLixte Biotechnology Holdings, Inc.-- -- -- -$2M ALNYAlnylam Pharmaceuticals, Inc.13.46x 1,364.49x $1.2B $251.1M
-
Which has Higher Returns LIXT or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -- compared to Lixte Biotechnology Holdings, Inc.'s net margin of -3.91%. Lixte Biotechnology Holdings, Inc.'s return on equity of -228.97% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.
Company Gross Margin Earnings Per Share Invested Capital LIXTLixte Biotechnology Holdings, Inc.-- -$0.33 $4.9M BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B -
What do Analysts Say About LIXT or BMRN?
Lixte Biotechnology Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $89.09 which suggests that it could grow by 56.1%. Given that BioMarin Pharmaceutical, Inc. has higher upside potential than Lixte Biotechnology Holdings, Inc., analysts believe BioMarin Pharmaceutical, Inc. is more attractive than Lixte Biotechnology Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LIXTLixte Biotechnology Holdings, Inc.0 0 0 BMRNBioMarin Pharmaceutical, Inc.14 6 0 -
Is LIXT or BMRN More Risky?
Lixte Biotechnology Holdings, Inc. has a beta of 0.929, which suggesting that the stock is 7.054% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.
-
Which is a Better Dividend Stock LIXT or BMRN?
Lixte Biotechnology Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lixte Biotechnology Holdings, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LIXT or BMRN?
Lixte Biotechnology Holdings, Inc. quarterly revenues are --, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. Lixte Biotechnology Holdings, Inc.'s net income of -$2M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, Lixte Biotechnology Holdings, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 21.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lixte Biotechnology Holdings, Inc. is -- versus 3.68x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LIXTLixte Biotechnology Holdings, Inc.-- -- -- -$2M BMRNBioMarin Pharmaceutical, Inc.3.68x 21.78x $786.8M -$30.7M
-
Which has Higher Returns LIXT or IMNN?
Imunon, Inc. has a net margin of -- compared to Lixte Biotechnology Holdings, Inc.'s net margin of --. Lixte Biotechnology Holdings, Inc.'s return on equity of -228.97% beat Imunon, Inc.'s return on equity of -365%.
Company Gross Margin Earnings Per Share Invested Capital LIXTLixte Biotechnology Holdings, Inc.-- -$0.33 $4.9M IMNNImunon, Inc.-- -$1.16 $5.2M -
What do Analysts Say About LIXT or IMNN?
Lixte Biotechnology Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Imunon, Inc. has an analysts' consensus of $21.50 which suggests that it could grow by 644.14%. Given that Imunon, Inc. has higher upside potential than Lixte Biotechnology Holdings, Inc., analysts believe Imunon, Inc. is more attractive than Lixte Biotechnology Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LIXTLixte Biotechnology Holdings, Inc.0 0 0 IMNNImunon, Inc.3 1 0 -
Is LIXT or IMNN More Risky?
Lixte Biotechnology Holdings, Inc. has a beta of 0.929, which suggesting that the stock is 7.054% less volatile than S&P 500. In comparison Imunon, Inc. has a beta of 2.135, suggesting its more volatile than the S&P 500 by 113.504%.
-
Which is a Better Dividend Stock LIXT or IMNN?
Lixte Biotechnology Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Imunon, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lixte Biotechnology Holdings, Inc. pays -- of its earnings as a dividend. Imunon, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LIXT or IMNN?
Lixte Biotechnology Holdings, Inc. quarterly revenues are --, which are smaller than Imunon, Inc. quarterly revenues of --. Lixte Biotechnology Holdings, Inc.'s net income of -$2M is higher than Imunon, Inc.'s net income of -$3.4M. Notably, Lixte Biotechnology Holdings, Inc.'s price-to-earnings ratio is -- while Imunon, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lixte Biotechnology Holdings, Inc. is -- versus 16.43x for Imunon, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LIXTLixte Biotechnology Holdings, Inc.-- -- -- -$2M IMNNImunon, Inc.16.43x -- -- -$3.4M
-
Which has Higher Returns LIXT or SVRA?
Savara, Inc. has a net margin of -- compared to Lixte Biotechnology Holdings, Inc.'s net margin of --. Lixte Biotechnology Holdings, Inc.'s return on equity of -228.97% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital LIXTLixte Biotechnology Holdings, Inc.-- -$0.33 $4.9M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About LIXT or SVRA?
Lixte Biotechnology Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 104.01%. Given that Savara, Inc. has higher upside potential than Lixte Biotechnology Holdings, Inc., analysts believe Savara, Inc. is more attractive than Lixte Biotechnology Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LIXTLixte Biotechnology Holdings, Inc.0 0 0 SVRASavara, Inc.6 0 0 -
Is LIXT or SVRA More Risky?
Lixte Biotechnology Holdings, Inc. has a beta of 0.929, which suggesting that the stock is 7.054% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.
-
Which is a Better Dividend Stock LIXT or SVRA?
Lixte Biotechnology Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lixte Biotechnology Holdings, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LIXT or SVRA?
Lixte Biotechnology Holdings, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. Lixte Biotechnology Holdings, Inc.'s net income of -$2M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Lixte Biotechnology Holdings, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lixte Biotechnology Holdings, Inc. is -- versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LIXTLixte Biotechnology Holdings, Inc.-- -- -- -$2M SVRASavara, Inc.-- -- -- -$29.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 9
Bill Holdings, Inc. [BILL] is up 3.7% over the past day.
Buy
75
PRLB alert for Feb 9
Proto Labs, Inc. [PRLB] is down 2.16% over the past day.
Sell
30
MSTR alert for Feb 9
Strategy, Inc. [MSTR] is up 2.59% over the past day.
